Quantum Genomics Corp. Partners with INSERM in Stroke and Cardiac Ischemia Drug Development

JERSEY CITY, N.J.--(BUSINESS WIRE)--Quantum Genomics Corp. (QGC), a global biotech company developing new drugs for metabolic and cardiovascular diseases, announces today a partnership agreement with Inserm, the French national institute for health and medical research and Universities Paris Descartes and Paris XII Val-de-Marne. This is the second lead molecule that QGC is developing through an agreement that brings together some of the leading scientific skills in the field of cardiovascular diseases.

Back to news